[ad_1]
Dublin, February 13, 2019 (GLOBE NEWSWIRE) – The report "Antiviral Therapeutics – Technologies, Markets & Companies" by Jain PharmaBiotech has been added to ResearchAndMarkets.com & # 39; s offer.
This report reviews the current state of antiviral approaches, including vaccines, pharmaceuticals and innovative technologies for the delivery of therapeutic products.
The introduction begins with a practical clbadification of viral diseases according to their commercial importance. Various antiviral approaches are described, including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi), as well as vaccines against viral infections. Expert advice is given on current problems and needs in antiviral therapy. The SWOT badysis (strengths, weaknesses, opportunities and threats) of antiviral approaches is presented in the context of the ideal antiviral agent concept.
A novelty of this report is the use of nanotechnology in virology and its potential for antiviral treatment. The interaction of nanoparticles with viruses is described. Nanoviricides are polymeric micelles that act as nanomedicines to destroy viruses. Various methods for the local and systemic delivery of antiviral agents and vaccines are described. Nanobiotechnologies play an important role in improving the delivery of antivirals. The benefits and limitations of administering antiviral therapies based on genes, antisense and RNAi are discussed.
Anti-influenza measures for the human and avian forms are described, including the recent swine flu outbreak. Resistance may develop against neuraminidase inhibitors although it is lower than that of adamantanes. Given these problems, a more effective agent is needed. Research on other influenza targets is likely to develop in the years to come. These include the development of mechanisms to inhibit the fusion between the envelope of the virus and the cell membrane.
After a discussion of current HIV / AIDS treatments and their limitations, new strategies for the development of antiviral agents are described. Drug resistance and toxicities are becoming a major challenge for treatment. On the basis of a review of developing technologies and drugs, it can be argued that there is a good prospect of finding a cure for HIV / AIDS in the next decade.
Hepatitis viruses are described, especially the viruses of hepatitis C (HCV) and hepatitis B (HBV). Despite the presence of many drug candidates in the anti-HCV pipeline and the commitment of many pharmaceutical companies to R & D resources, several new anti-HCV drugs could take several years to reach the market. Although many companies are focusing their efforts on the development of viral inhibitors, host cell targets are beginning to appear as exciting possibilities because they could allow the development of antiviral drugs to be broadly based. spectrum with less chance of developing viral resistance.
Various commercially important viruses include herpes simplex (HSV) and human papillomavirus (HPV). There are a number of treatments, but HSV is not completely destroyed, remains dormant and activates from time to time to cause various clinical manifestations. The role of HPV in cervical cancer is discussed and currently available vaccines seem sufficient to prevent HSV – induced cervical cancer. There is no effective vaccine against respiratory syncytial virus (RSV), although monoclonal antibody (MAb) therapy is useful for prophylaxis and reduction of clinical manifestations. An agent is needed to eliminate this virus.
Various viruses appearing during epidemics or in the tropics and some naturally emerging infectious diseases are described, for example: viral haemorrhagic fevers such as dengue fever and West Nile virus. These constitute a constant threat and impossible to anticipate. Some of them lack antivirals or preventative vaccines. Although these include some of the most serious viral disorders, the development of antiviral agents for them is not commercially attractive. Current research and approaches to these viral infections are discussed.
Antiviral markets are considered in terms of the viruses and diseases they cause as well as management approaches: antiviral drugs, vaccines, monoclonal antibodies and innovative approaches including immunology and the use of other technologies such as therapy. genetics, antisense, RNAi and nanobiotechnologies. Antiviral markets are estimated from 2017 and forecasts to the 2027 horizon.
The profiles of 194 companies involved in the development of various technologies and products are presented with 175 collaborations. These include large pharmaceutical companies (12), biopharmaceutical companies offering antiviral products (86), antiviral drug companies (26) and viral vaccine companies (71). The report is completed by 53 tables, 15 figures and 550 references in the literature.
Key topics covered:
summary
1. Introduction to virology
2. Antiviral approaches
3. Vaccines against viral infections
4. Role of nanotechnology in the development of antiviral agents
5. Delivery of antivirals
6. Competitive evaluation of antiviral approaches
7. Influenza virus
8. AIDS / HIV
9. Hepatitis virus
10. Various viral infections important in the trade
11. High impact virus but of low commercial importance
12. Markets for antivirals
13. companies
14. references
For more information on this report, visit https://www.researchandmarkets.com/research/v3nfkh/global_antiviral?w=12.
Source: Jain PharmaBiotech
Research and Markets also offers customized research services that provide targeted, comprehensive and personalized research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Secretary [email protected] For office hours, call 1-917-300-0470 For toll-free calls to the United States and Canada: 1-800-526-8630 For GMT office hours, call + 353-1-416-8900 Related Topics: Infectious Diseases Drugs
Source link
